Abstract: A method of making a glass includes batching constituents, including silica, alumina, boria, magnesia, quicklime, and strontia, where one or more of the constituents is from “dirty” raw material that includes a relatively large amount of sulfur. The method further includes melting and mixing the batch to make glass having sulfur content but free of blisters, suitable for high performance displays.

Abstract: This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

Abstract: The present invention relates to inhalable formulations, and kits and methods suitable for the preparation of such inhalable formulations. The inhalable formulations comprise a freebase of a deuterium-substituted dimethyltryptamine compound. The inhalable formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.

Abstract: Described herein are compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.

Abstract: The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.

Abstract: The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.

Abstract: The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg/ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.

Abstract: Compounds, compositions, methods, and uses are described for therapeutic deuterated N,N-dimethyltryptamine compounds (e.g., a single compound or a plurality of deuterated N,N-dimethyltryptamine compounds) such as N,N-dimethyltryptamine compounds, ?-protio, ?-deutero-N,N-dimethyltryptamine compounds, ?,?-dideutero-N,N-dimethyltryptamine compounds, and pharmaceutically acceptable salts of these compounds. The deuterated N,N-dimethyltryptamine compound may have an increased half-life compared with the half-life of undeuterated N,N-dimethyltryptamine. For example, a deuterated N,N-dimethyltryptamine compound may be used in therapy and have a Formula (I): wherein: the ratio of deuterium:protium in the compound is greater than that found naturally in hydrogen; each R1 is independently selected from H and D; R2 is selected from CH3 and CD3; R3 is selected from CH3 and CD3; each yH is independently selected from H and D, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.

Abstract: The present invention relates to compositions comprising compounds of formula I and II. These compositions have uses in the treatment of psychiatric or neurological disorders. Varying the relative amounts of the compounds of formula I and II within the compositions is expected to modulate the therapeutic effect. Related compounds of formula Ill comprise d3-monomethylamino or d6-dimethylamino groups and are useful internal standards for quantifying the amount of a target compound, such as an analogous compound comprising protio-monomethylamino or protio-dimethylamino groups. Thus, the present invention also relates to compounds of formula Ill and their uses as internal standards in assays for quantifying the amount of a target compound in a sample. A method of quantifying the amount of a target compound in a sample by adding a known amount of a compound of formula Ill to the sample is also included.

Abstract: Described herein are compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.

Abstract: Compounds, compositions, methods, and uses are described for therapeutic deuterated N,N-dimethyltryptamine compounds (e.g., a single compound or a plurality of deuterated N,N-dimethyltryptamine compounds) such as N,N-dimethyltryptamine compounds, ?-protio, ?-deutero-N,N-dimethyltryptamine compounds, ?,?-dideutero-N,N-dimethyltryptamine compounds, and pharmaceutically acceptable salts of these compounds. The deuterated N,N-dimethyltryptamine compound may have an increased half-life compared with the half-life of undeuterated N,N-dimethyltryptamine. For example, a deuterated N,N-dimethyltryptamine compound may be used in therapy and have a Formula (I): wherein: the ratio of deuterium:protium in the compound is greater than that found naturally in hydrogen; each R1 is independently selected from H and D; R2 is selected from CH3 and CD3; R3 is selected from CH3 and CD3; each yH is independently selected from H and D, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a solid dosage form comprising two or more compounds selected from N,N-dimethyltryptamine and its deuterated analogues and pharmaceutically acceptable salts thereof, and methods of treatment (e.g., of a psychiatric disorder or a neurological disorder) comprising administering the solid dosage form to a patient in need thereof.

Abstract: This invention relates to high concentration solid oral dosage forms of a ketamine metabolite selected from 2R,6R-hydroxynorketamine, 2S,6S-hydroxynorketamine, R-5,6-dehydronorketamine and S-5,6-dehydronorketamine.

Abstract: Manipulation and regulation of power provided by a time-varying power source to continuously provide power to a load by insuring that any minimum voltage or current requirements of the load are met even when the power provided by the time-varying power source itself does not satisfy the load's minimum voltage or current requirements. For a load having a minimum voltage requirement, power from a time varying source will be boosted as necessary to insure that the minimum voltage is maintained.

Abstract: A power controller which includes a boost pre-regulator receiving power from a power source providing an input voltage and an input current, and having compensation networks which are dynamically adjusted for power level, the pre-regulator providing power factor correction to maintain a total harmonic distortion of the input current of 2-3% at full power, and less than 5% at all power levels, while the input voltage is anywhere within the range of 95 to 265 VAC; and a forward converter receiving control from a current-mode controller which is in turn under the control of the boost pre-regulator, in order to achieve substantially constant duty cycle of the forward converter over the entire range of power levels.

Abstract: Manipulation and regulation of power provided by a time-varying power source to continuously provide power to a load by insuring that any minimum voltage or current requirements of the load are met even when the power provided by the time-varying power source itself does not satisfy the load's minimum voltage or current requirements. For a load having a minimum voltage requirement, power from a time varying source will be boosted as necessary to insure that the minimum voltage is maintained.

Abstract: A power controller which includes a boost pre-regulator receiving power from a power source providing an input voltage and an input current, and having compensation networks which are dynamically adjusted for power level, the pre-regulator providing power factor correction to maintain a total harmonic distortion of the input current of 2-3% at full power, and less than 5% at all power levels, while the input voltage is anywhere within the range of 95 to 265 VAC; and a forward converter receiving control from a current-mode controller which is in turn under the control of the boost pre-regulator, in order to achieve substantially constant duty cycle of the forward converter over the entire range of power levels.

Abstract: An onboard electric vehicle charger is provided which incorporates a forward converter with dynamic balancing of the primary drive currents of its ferrite core transformer to produce 5,000 watt charging power with a power density of 333 watts per kilogram and full safety isolation between the input power source and the batteries plus small size (approximately 15″ by 9″ by 6″) and weight (less than 15 kilograms) and a power factor correcting boost preregulator with dynamic adjustment of its compensation networks which produces full correction to substantially unity (99.9+%) for power factor with current total harmonic distortion (THD) of 2% to 3% over the entire power range of 100 watts to 5,000 watts. The same boost preregulator circuit allows operation from power sources of 95 to 145 VAC or 200 to 275 VAC.

Abstract: An onboard electric vehicle charger is provided which incorporates a forward converter with dynamic balancing of the primary drive currents of its ferrite core transformer to produce 5,000 watt charging power with a power density of 333 watts per kilogram and full safety isolation between the input power source and the batteries plus small size (approximately 15" by 9" by 6") and weight (less than 15 kilograms) and a power factor correcting boost preregulator with dynamic adjustment of its compensation networks which produces full correction to substantially unity (99.9+%) for power factor with current total haromonic distortion (THD) of 2% to 3% over the entire power range of 100 watts to 5,000 watts. The same boost preregulator circuit allows operation from power sources of 95 to 145 VAC or 200 to 275 VAC.